

COVID-19 vaccines – FDA makes recommendations for new monovalent vaccine composition for 2024-2025

- On June 13, 2024, the <u>FDA advised</u> that the preferred JN.1-lineage for the COVID-19 vaccines (2024 - 2025 formula) is the KP.2 strain, if feasible.
 - On June 5, 2024, the FDA's <u>Vaccine and Related Biological Products Advisory</u> <u>Committee (VRBPAC)</u> unanimously voted for the 2024 - 2025 formula of COVID-19 vaccines in the U.S. to include a monovalent JN.1-lineage.
- This change of recommending the KP.2 strain is intended to ensure that the COVID-19 vaccines (2024 2025 formula) more closely match circulating SARS-CoV-2 strains.
- Based on the <u>CDC's COVID Data Tracker</u>, as of June 8, 2024, the KP.2 strain makes up 22.5% of COVID cases and the KP.3 strain makes up 25% of the cases.

What's Next?

- Vaccine manufacturers will submit their 2024 2025 formula COVID vaccines to the FDA for approval.
- The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) will meet on <u>June 27, 2024</u> to discuss and make recommendations on the FDA's approvals.
- The new vaccines are expected to be available in the August 2024 timeframe.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.